A Case of Prurigo Nodularis Treated with Dupilumab
- Author:
Donghoon LEE
1
;
Gayun BAEK
;
Jiyoon BAEK
;
Hyun Ji KANG
;
Min-Soo KIM
;
Mihn-Sook JUE
Author Information
1. Department of Dermatology, Veterans Health Service Medical Center, Seoul, Korea
- Publication Type:Case Report
- From:Korean Journal of Dermatology
2022;60(10):687-691
- CountryRepublic of Korea
- Language:English
-
Abstract:
Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by multiple nodules and papules, which are accompanied by intense pruritus. Treatment is challenging and requires a diverse approach. Recently, a few reports have described successful treatment of PN with dupilumab. We report a case of a patient with treatment-resistant PN who was successfully treated with dupilumab. Dupilumab was administered at the standard dose: an initial induction dose of 600 mg, followed by 300 mg every 14 days. Pruritus reduced after 2 weeks and almost completely disappeared after 4 weeks of treatment.
